These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9073527)

  • 1. Safety evaluation of recombinant human interleukin-4. II. Clinical studies.
    Leach MW; Rybak ME; Rosenblum IY
    Clin Immunol Immunopathol; 1997 Apr; 83(1):12-4. PubMed ID: 9073527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety evaluation of recombinant human interleukin-4. I. Preclinical studies.
    Leach MW; Snyder EA; Sinha DP; Rosenblum IY
    Clin Immunol Immunopathol; 1997 Apr; 83(1):8-11. PubMed ID: 9073526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial.
    Gilleece MH; Scarffe JH; Ghosh A; Heyworth CM; Bonnem E; Testa N; Stern P; Dexter TM
    Br J Cancer; 1992 Jul; 66(1):204-10. PubMed ID: 1637669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of continuous infusion recombinant human interleukin-4 in patients with cancer.
    Majhail NS; Hussein M; Olencki TE; Budd GT; Wood L; Elson P; Bukowski RM
    Invest New Drugs; 2004 Nov; 22(4):421-6. PubMed ID: 15292712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical safety evaluation of recombinant human interleukin-10.
    Rosenblum IY; Johnson RC; Schmahai TJ
    Regul Toxicol Pharmacol; 2002 Feb; 35(1):56-71. PubMed ID: 11846636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pathologic alterations associated with subcutaneous administration of recombinant human interleukin-4 to cynomolgus monkeys.
    Gossett KA; Barbolt TA; Cornacoff JB; Zelinger DJ; Dean JH
    Toxicol Pathol; 1993; 21(1):46-53. PubMed ID: 8378706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of recombinant human interleukin-4.
    Cornacoff JB; Gossett KA; Barbolt TA; Dean JH
    Toxicol Lett; 1992 Dec; 64-65 Spec No():299-310. PubMed ID: 1471185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma.
    Motzer RJ; Rakhit A; Thompson JA; Nemunaitis J; Murphy BA; Ellerhorst J; Schwartz LH; Berg WJ; Bukowski RM
    J Interferon Cytokine Res; 2001 Apr; 21(4):257-63. PubMed ID: 11359657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group.
    Campion GV; Lebsack ME; Lookabaugh J; Gordon G; Catalano M
    Arthritis Rheum; 1996 Jul; 39(7):1092-101. PubMed ID: 8670316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I and pharmacokinetic study of subcutaneously-administered recombinant human interleukin-4 (rhuIL-4) in patients with advanced cancer.
    Davis ID; Maher DW; Cebon JS; Green MD; Fox RM; McKendrick JJ; Rybak ME; Boyd AW
    Growth Factors; 2000; 17(4):287-300. PubMed ID: 10801077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of recombinant human interleukin-4 for advanced or recurrent non-small cell lung cancer.
    Vokes EE; Figlin R; Hochster H; Lotze M; Rybak ME
    Cancer J Sci Am; 1998; 4(1):46-51. PubMed ID: 9467046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical safety of recombinant human interleukin-18.
    Herzyk DJ; Bugelski PJ; Hart TK; Wier PJ
    Toxicol Pathol; 2003; 31(5):554-61. PubMed ID: 14692624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group.
    Fedorak RN; Gangl A; Elson CO; Rutgeerts P; Schreiber S; Wild G; Hanauer SB; Kilian A; Cohard M; LeBeaut A; Feagan B
    Gastroenterology; 2000 Dec; 119(6):1473-82. PubMed ID: 11113068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pleiotropic effects of cytokines: clinical and preclinical studies.
    Bukowski RM; Olencki T; McLain D; Finke JH
    Stem Cells; 1994; 12 Suppl 1():129-40; discussion 140-1. PubMed ID: 7696957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri).
    Sarmiento UM; Riley JH; Knaack PA; Lipman JM; Becker JM; Gately MK; Chizzonite R; Anderson TD
    Lab Invest; 1994 Dec; 71(6):862-73. PubMed ID: 7807968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis.
    Drevlow BE; Lovis R; Haag MA; Sinacore JM; Jacobs C; Blosche C; Landay A; Moreland LW; Pope RM
    Arthritis Rheum; 1996 Feb; 39(2):257-65. PubMed ID: 8849376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombopoietic activity of recombinant human interleukin 11 (rHuIL-11) in normal and myelosuppressed nonhuman primates.
    Schlerman FJ; Bree AG; Kaviani MD; Nagle SL; Donnelly LH; Mason LE; Schaub RG; Grupp SA; Goldman SJ
    Stem Cells; 1996 Sep; 14(5):517-32. PubMed ID: 8888493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histomorphologic observations for cynomolgus monkeys after subchronic subcutaneous injection of recombinant human interleukin-4.
    Barbolt TA; Gossett KA; Cornacoff JB
    Toxicol Pathol; 1991; 19(3):251-7. PubMed ID: 1780642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C.
    Zeuzem S; Hopf U; Carreno V; Diago M; Shiffman M; Grüne S; Dudley FJ; Rakhit A; Rittweger K; Yap SH; Koff RS; Thomas HC
    Hepatology; 1999 Apr; 29(4):1280-7. PubMed ID: 10094976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies.
    Weber J; Yang JC; Topalian SL; Parkinson DR; Schwartzentruber DS; Ettinghausen SE; Gunn H; Mixon A; Kim H; Cole D
    J Clin Oncol; 1993 Mar; 11(3):499-506. PubMed ID: 7680375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.